摘要
目的:系统地综述中国多发性骨髓瘤(MM)的治疗现状及药物经济学研究。方法:通过检索国内数据库,对现有已公开发表的相关文献和出版物,从治疗现状和药物经济学研究方面进行汇总、梳理、分析。结果与结论:现有已公开发表的文献均显示随着MM治疗指南的发展和新药的上市,我国MM治疗也有了很大进展。但由于目前诊断及预后评估体系缺乏广泛应用,MM流行病学、疾病负担、新药以及自体移植应用之后生存获益的具体数据和相应的药物经济学研究数据缺乏,中国MM治疗仍面临较大挑战。
Objective： To systematically review on the current situation of and pharmacoeconomic researches on multiple myeloma （MM） treatment in China. Methods： Based on literatures and publications, this study employed a descriptive research to summarize and analyze the related data. Result and Conclusion： With updated NCCN clinical practice guidelines and new medicines coming into markets, a great progress has been made in the treatment of MM in China. But it is still facing significant challenges because of lacking widely used diagnosis and prognosis evaluation system, epidemiological data, disease burden analysis, survival benefit and corresponding cost effectiveness evaluation on new drugs and autologous stem cell transplantation, and high-quality and comprehensive pharmacoeconomic researches.
出处
《中国医疗保险》
2015年第9期57-59,共3页
China Health Insurance
关键词
多发性骨髓瘤
治疗现状
药物经济学
multiple myeloma （MM）, current treatment, pharmacoeconomics
